GlobalData on MSN

Actinogen treats first patient in XanaMIA trial for Alzheimer’s

Actinogen anticipates final topline efficacy and safety results for the full 36-week treatment period in November 2026.

Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update

Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) ...
Managed Healthcare Executive

Attruby reduces risk of death by 49% in rare heart condition in long-term study

A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid ...

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy.
Nasdaq

Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
BioSpace

FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls

While recent FDA guidance speaks to the agency’s support of innovative trial designs—including the use of external ...
Stocktwits on MSN

IBRX stock eyes breakout quarter: Anktiva enters phase 2 long COVID trial as Europe expansion plans emerge

The company launched a Phase 2 Long COVID study to evaluate whether immune activation with Anktiva can improve recovery by ...
ascopubs.org

An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors.

Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL). A novel application of deep ...